U.S. flag

An official website of the United States government

Format

Send to:

Choose Destination

Unresectable Lung Non-Squamous Non-Small Cell Carcinoma

MedGen UID:
1690099
•Concept ID:
C5206715
•
Neoplastic Process

Definition

Lung non-squamous non-small cell carcinoma that is not amenable to surgical resection. [from NCI]

Term Hierarchy

CClinical test,  RResearch test,  OOMIM,  GGeneReviews,  VClinVar  
  • CROGVUnresectable Lung Non-Squamous Non-Small Cell Carcinoma

Professional guidelines

PubMed

Role of CTLA Inhibition in Management of Non-Small Cell Lung Cancer.
Kerrigan K, Puri S
Curr Oncol Rep 2022 Jan;24(1):113-123. Epub 2022 Jan 20 doi: 10.1007/s11912-021-01164-1. PMID: 35060001
Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
Saxena P, Singh PK, Malik PS, Singh N
Curr Treat Options Oncol 2020 Jul 27;21(8):69. doi: 10.1007/s11864-020-00768-2. PMID: 32720019
Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
Aita M, Fasola G, Defferrari C, Brianti A, Bello MG, Follador A, Sinaccio G, Pronzato P, Grossi F
Crit Rev Oncol Hematol 2008 Dec;68(3):183-96. Epub 2008 Jul 7 doi: 10.1016/j.critrevonc.2008.05.002. PMID: 18606548

Recent clinical studies

Etiology

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
Smit EF, Felip E, Uprety D, Nagasaka M, Nakagawa K, Paz-Ares Rodríguez L, Pacheco JM, Li BT, Planchard D, Baik C, Goto Y, Murakami H, Saltos A, Pereira K, Taguchi A, Cheng Y, Yan Q, Feng W, Tsuchihashi Z, Jänne PA
Lancet Oncol 2024 Apr;25(4):439-454. doi: 10.1016/S1470-2045(24)00064-0. PMID: 38547891
EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis.
Kim H, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ
Cancer Res Treat 2023 Apr;55(2):498-505. Epub 2022 Oct 4 doi: 10.4143/crt.2022.388. PMID: 36228655Free PMC Article
Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges.
Aggarwal C, Bubendorf L, Cooper WA, Illei P, Borralho Nunes P, Ong BH, Tsao MS, Yatabe Y, Kerr KM
Lung Cancer 2021 Dec;162:42-53. Epub 2021 Sep 15 doi: 10.1016/j.lungcan.2021.09.003. PMID: 34739853
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.
Shi Y, Lei K, Jia Y, Ni B, He Z, Bi M, Wang X, Shi J, Zhou M, Sun Q, Wang G, Chen D, Shu Y, Liu L, Guo Z, Liu Y, Yang J, Wang K, Xiao K, Wu L, Yi T, Sun D, Kang M, Ma T, Mao Y, Shi J, Tang T, Wang Y, Xing P, Lv D, Liao W, Luo Z, Wang B, Wu X, Zhu X, Han S, Guo Q, Liu R, Lu Z, Zhang J, Fang J, Hu C, Ji Y, Liu G, Lu H, Wu D, Zhang J, Zhu S, Liu Z, Qiu W, Ye F, Yu Y, Zhao Y, Zheng Q, Chen J, Pan Z, Zhang Y, Lian W, Jiang B, Qiu B, Zhang G, Zhang H, Chen Y, Chen Y, Duan H, Li M, Liu S, Ma L, Pan H, Yuan X, Yuan X, Zheng Y, Gao E, Zhao L, Wang S, Wu C
Cancer Commun (Lond) 2021 Sep;41(9):889-903. Epub 2021 Jun 29 doi: 10.1002/cac2.12179. PMID: 34184418Free PMC Article
Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
Patel JD, Lee JW, Carbone DP, Wagner H, Shanker A, de Aquino MTP, Horn L, Johnson ML, Gerber DE, Liu JJ, Das MS, Al-Nsour MA, Dakhil CSR, Ramalingam S, Schiller JH
Clin Lung Cancer 2020 Nov;21(6):520-526. Epub 2020 Jun 12 doi: 10.1016/j.cllc.2020.06.007. PMID: 32807654Free PMC Article

Diagnosis

Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges.
Aggarwal C, Bubendorf L, Cooper WA, Illei P, Borralho Nunes P, Ong BH, Tsao MS, Yatabe Y, Kerr KM
Lung Cancer 2021 Dec;162:42-53. Epub 2021 Sep 15 doi: 10.1016/j.lungcan.2021.09.003. PMID: 34739853
Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
Saxena P, Singh PK, Malik PS, Singh N
Curr Treat Options Oncol 2020 Jul 27;21(8):69. doi: 10.1007/s11864-020-00768-2. PMID: 32720019
Durvalumab vs placebo consolidation therapy after chemoradiotherapy in stage III non-small-cell lung cancer: An updated PACIFIC trial-based cost-effectiveness analysis.
Han J, Tian K, Yang J, Gong Y
Lung Cancer 2020 Aug;146:42-49. Epub 2020 May 28 doi: 10.1016/j.lungcan.2020.05.011. PMID: 32512272
Long-term survival trends in patients with unresectable stage III non-small cell lung cancer receiving chemotherapy and radiation therapy: a SEER cancer registry analysis.
Hansen RN, Zhang Y, Seal B, Ryan K, Yong C, Darilay A, Ramsey SD
BMC Cancer 2020 Apr 5;20(1):276. doi: 10.1186/s12885-020-06734-3. PMID: 32248816Free PMC Article
A multicenter phase II study of docetaxel, oxaliplatin, and bevacizumab in first-line therapy for unresectable locally advanced or metastatic non-squamous cell histology non-small-cell lung cancer (NSCLC).
Raez LE, Santos ES, Webb RT, Wade J, Brito RA, Karr M, Kennah A, Childs BH
Cancer Chemother Pharmacol 2013 Nov;72(5):1103-10. Epub 2013 Sep 22 doi: 10.1007/s00280-013-2301-z. PMID: 24057043

Therapy

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
Smit EF, Felip E, Uprety D, Nagasaka M, Nakagawa K, Paz-Ares Rodríguez L, Pacheco JM, Li BT, Planchard D, Baik C, Goto Y, Murakami H, Saltos A, Pereira K, Taguchi A, Cheng Y, Yan Q, Feng W, Tsuchihashi Z, Jänne PA
Lancet Oncol 2024 Apr;25(4):439-454. doi: 10.1016/S1470-2045(24)00064-0. PMID: 38547891
EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis.
Kim H, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ
Cancer Res Treat 2023 Apr;55(2):498-505. Epub 2022 Oct 4 doi: 10.4143/crt.2022.388. PMID: 36228655Free PMC Article
Molecular testing in stage I-III non-small cell lung cancer: Approaches and challenges.
Aggarwal C, Bubendorf L, Cooper WA, Illei P, Borralho Nunes P, Ong BH, Tsao MS, Yatabe Y, Kerr KM
Lung Cancer 2021 Dec;162:42-53. Epub 2021 Sep 15 doi: 10.1016/j.lungcan.2021.09.003. PMID: 34739853
Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
Patel JD, Lee JW, Carbone DP, Wagner H, Shanker A, de Aquino MTP, Horn L, Johnson ML, Gerber DE, Liu JJ, Das MS, Al-Nsour MA, Dakhil CSR, Ramalingam S, Schiller JH
Clin Lung Cancer 2020 Nov;21(6):520-526. Epub 2020 Jun 12 doi: 10.1016/j.cllc.2020.06.007. PMID: 32807654Free PMC Article
Immunotherapy Alone or in Combination with Chemotherapy as First-Line Treatment of Non-Small Cell Lung Cancer.
Saxena P, Singh PK, Malik PS, Singh N
Curr Treat Options Oncol 2020 Jul 27;21(8):69. doi: 10.1007/s11864-020-00768-2. PMID: 32720019

Prognosis

EGFR Mutation-Positive Unresectable Stage III Non-Squamous Lung Cancer Is Associated with a High Incidence of Brain Metastasis.
Kim H, Park S, Jung HA, Sun JM, Lee SH, Ahn JS, Ahn MJ
Cancer Res Treat 2023 Apr;55(2):498-505. Epub 2022 Oct 4 doi: 10.4143/crt.2022.388. PMID: 36228655Free PMC Article
Final results of the IFCT-0803 study, a phase II study of cetuximab, pemetrexed, cisplatin, and concurrent radiotherapy in patients with locally advanced, unresectable, stage III, non-squamous, non-small-cell lung cancer.
Trédaniel J, Barlési F, Le Péchoux C, Lerouge D, Pichon É, Le Moulec S, Moreau L, Friard S, Westeel V, Petit L, Carré O, Guichard F, Raffy O, Villa J, Prévost A, Langlais A, Morin F, Wislez M, Giraud P, Zalcman G, Mornex F; French Cooperative Thoracic Intergroup (IFCT)
Cancer Radiother 2022 Sep;26(5):670-677. Epub 2022 Mar 5 doi: 10.1016/j.canrad.2021.12.005. PMID: 35260342
Phase II Study of Immunotherapy With Tecemotide and Bevacizumab After Chemoradiation in Patients With Unresectable Stage III Non-Squamous Non-Small-Cell Lung Cancer (NS-NSCLC): A Trial of the ECOG-ACRIN Cancer Research Group (E6508).
Patel JD, Lee JW, Carbone DP, Wagner H, Shanker A, de Aquino MTP, Horn L, Johnson ML, Gerber DE, Liu JJ, Das MS, Al-Nsour MA, Dakhil CSR, Ramalingam S, Schiller JH
Clin Lung Cancer 2020 Nov;21(6):520-526. Epub 2020 Jun 12 doi: 10.1016/j.cllc.2020.06.007. PMID: 32807654Free PMC Article
Impact of EGFR Mutation and ALK Translocation on Recurrence Pattern After Definitive Chemoradiotherapy for Inoperable Stage III Non-squamous Non-small-cell Lung Cancer.
Nakamura M, Kageyama SI, Niho S, Okumura M, Hojo H, Motegi A, Nakamura N, Zenda S, Yoh K, Goto K, Akimoto T
Clin Lung Cancer 2019 May;20(3):e256-e264. Epub 2019 Mar 4 doi: 10.1016/j.cllc.2019.02.021. PMID: 30926356
Emerging safety data for bevacizumab in advanced non-small-cell lung cancer.
Hirsh V
Clin Lung Cancer 2008 Mar;9 Suppl 2:S62-70. doi: 10.3816/CLC.2008.s.010. PMID: 21885001

Clinical prediction guides

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial.
Smit EF, Felip E, Uprety D, Nagasaka M, Nakagawa K, Paz-Ares Rodríguez L, Pacheco JM, Li BT, Planchard D, Baik C, Goto Y, Murakami H, Saltos A, Pereira K, Taguchi A, Cheng Y, Yan Q, Feng W, Tsuchihashi Z, Jänne PA
Lancet Oncol 2024 Apr;25(4):439-454. doi: 10.1016/S1470-2045(24)00064-0. PMID: 38547891
Durvalumab in combination with chemoradiotherapy for patients with unresectable stage III non-small-cell lung cancer: Results from the phase 1 CLOVER study.
Kim DW, Chul Cho B, Pachipala K, Kim SW, Wang CL, Chang GC, Ahn MJ, Alvarez R, Chiu CH, Trigo J, Estival A, Karam SD, O'Brien C, Gowda H, Jiang H, Bauman JE
Lung Cancer 2024 Apr;190:107530. Epub 2024 Mar 7 doi: 10.1016/j.lungcan.2024.107530. PMID: 38471416
Bevacizumab biosimilar LY01008 compared with bevacizumab (Avastin) as first-line treatment for Chinese patients with unresectable, metastatic, or recurrent non-squamous non-small-cell lung cancer: A multicenter, randomized, double-blinded, phase III trial.
Shi Y, Lei K, Jia Y, Ni B, He Z, Bi M, Wang X, Shi J, Zhou M, Sun Q, Wang G, Chen D, Shu Y, Liu L, Guo Z, Liu Y, Yang J, Wang K, Xiao K, Wu L, Yi T, Sun D, Kang M, Ma T, Mao Y, Shi J, Tang T, Wang Y, Xing P, Lv D, Liao W, Luo Z, Wang B, Wu X, Zhu X, Han S, Guo Q, Liu R, Lu Z, Zhang J, Fang J, Hu C, Ji Y, Liu G, Lu H, Wu D, Zhang J, Zhu S, Liu Z, Qiu W, Ye F, Yu Y, Zhao Y, Zheng Q, Chen J, Pan Z, Zhang Y, Lian W, Jiang B, Qiu B, Zhang G, Zhang H, Chen Y, Chen Y, Duan H, Li M, Liu S, Ma L, Pan H, Yuan X, Yuan X, Zheng Y, Gao E, Zhao L, Wang S, Wu C
Cancer Commun (Lond) 2021 Sep;41(9):889-903. Epub 2021 Jun 29 doi: 10.1002/cac2.12179. PMID: 34184418Free PMC Article
Phase 2 Study of Nimotuzumab in Combination With Concurrent Chemoradiotherapy in Patients With Locally Advanced Non-Small-Cell Lung Cancer.
Yamamoto N, Harada H, Okamoto I, Masuda N, Hayakawa K, Satouchi M, Soejima T, Nishio M, Kozuka T, Takeda K, Tanaka M, Seto T, Sasaki T, Tsubouchi H, Kakurai Y, Nishimura Y, Nakagawa K
Clin Lung Cancer 2021 Mar;22(2):134-141. Epub 2020 Dec 26 doi: 10.1016/j.cllc.2020.12.012. PMID: 33518480
Impact of EGFR Mutation and ALK Translocation on Recurrence Pattern After Definitive Chemoradiotherapy for Inoperable Stage III Non-squamous Non-small-cell Lung Cancer.
Nakamura M, Kageyama SI, Niho S, Okumura M, Hojo H, Motegi A, Nakamura N, Zenda S, Yoh K, Goto K, Akimoto T
Clin Lung Cancer 2019 May;20(3):e256-e264. Epub 2019 Mar 4 doi: 10.1016/j.cllc.2019.02.021. PMID: 30926356

Supplemental Content

Table of contents

    Practice guidelines

    • PubMed
      See practice and clinical guidelines in PubMed. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.
    • Bookshelf
      See practice and clinical guidelines in NCBI Bookshelf. The search results may include broader topics and may not capture all published guidelines. See the FAQ for details.

    Related information

    • PMC Articles
      Related information in PubMed Central Links
    • PubMed
      Related literature resources in PubMed

    Recent activity

    Clear Turn Off Turn On

    Your browsing activity is empty.

    Activity recording is turned off.

    Turn recording back on

    See more...